Kornimate/medical-research-clean huggingface dataset:
letrozole in preventing recurrence of endometrioma following laparoscopic ovarian cystectomy

Conditions: Endometriotic Cyst of Ovary

Summary: endometriosis is a chronic inflammatory disease that affects approximately 10-15% of women of reproductive age. symptoms include dysmenorrhoea, chronic pelvic pain, dyspareunia and infertility. removal of the endometriotic cyst (chocolate cyst) by surgery is a well-established treatment for symptomatic relief. however, recurrence of endometriotic cyst after surgical removal of the cyst is up to 30-50% after ovarian surgery. oral contraceptive pills for 18-24 months after the surgery is widely used as a postoperative hormonal therapy because it has been shown to reduce the chance of recurrence of the endometriotic cyst, but recurrence is still high even after taking oral contraceptive pills. letrozole is an aromatase inhibitor. there are some preliminary reports that letrozole can cause shrinkage of endometriotic cysts and improve endometriosis-related pelvic pain by reducing oestrogen level, inflammation and stem cell recruitment that may be important in recurrence of endometriotic cyst. this is a randomized double-blinded placebo-controlled trial. the aim of this study is to assess whether taking letrozole in addition to oral contraceptive pills in the first 6 months after laparoscopic surgery (key-hole surgery) to remove the endometriotic cyst can reduce the risk of recurrence compared to oral contraceptive pills alone. the study also involves laboratory parts from a small portion of the endometriotic cyst specimens (removed during laparoscopy ovarian cystectomy) and endometrial biopsy (if the patient agrees) to assess the role of stem cells in the pathogenesis of endometriotic cysts.


Eligibility criteria:
inclusion criteria: * women aged 18-45 years old * scheduled to have laparoscopic ovarian cystectomy * unilateral or bilateral endometrioma on pre-operative ultrasound and confirmed by histology exclusion criteria: * use of long-acting hormonal therapy in the 3 months before inclusion in the study * histological report of laparoscopic ovarian cystectomy showed atypical endometrioma * complex surgery including resection of deep infiltrating disease, bowel resection or hysterectomy * incomplete excision of endometrioma/ incision or drainage rather than ovarian cystectomy * suspicion of malignancy * contraindications to combined oral contraceptive pills, including: uncontrolled hypertension (systolic \> 160mmhg or diastolic \> 100mmhg), diabetes with retinopathy/ nephropathy/ neuropathy, current or past history of venous thromboembolism, ischemic heart disease, history of cerebrovascular accident, migraine with aura, severe liver disease, oestrogen-sensitive cancers, undiagnosed abnormal uterine bleeding, smokers (\> 15 cigarettes/day) aged 35 years or above, or having body mass index \>=35 kg/m2 * planning to get pregnant in the coming 1 year * refusal to join the study

Keywords: endometriotic cyst recurrence letrozole combined oral contraceptive pills
a study of medi9253 in combination with durvalumab in select solid tumors

Conditions: Solid Tumors

Summary: study d7880c00001 is a first-in-human (fih), phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pk, pharmacodynamics, and preliminary efficacy of medi9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.

up to approximately 192 participants may be assigned to study intervention in the study across approximately 30 sites globally.

Eligibility criteria:
inclusion criteria: 1. participant must be at least 18 years old at signing of informed consent. 2. body weight \> 35 kg at screening exclusion criteria: 1 primary central nervous system (cns) disease is excluded, as well as untreated or uncontrolled metastatic cns involvement, leptomeningeal disease, or cord compression. note: cns disease that has been treated and stable/controlled for at least 3 months is permitted. participants with cns disease controlled via systemic steroids are not permitted.

Keywords: solid tumors
sensors prediction study

Conditions: Injury Leg

Summary: the purpose of this study is to test whether measures of balance and agility can help predict if a service member may be at risk for an injury to their legs before beginning their school and training.


Eligibility criteria:
inclusion criteria: 1. between the ages of 18-55 2. active duty service members in the 82nd airborne division (abn div) 3. fluent in english speak and reading exclusion criteria: 1. service members under the age of 18 or over the age of 55 will be excluded 2. told by a doctor that they should not exercise. 3. orthopedic injury/surgery of the lower limb or back within the last year and that limits study compliance 4. regular use of medications that may alter balance, coordination or agility 5. unwilling to comply with the study protocol

Keywords: hip injury knee injury ankle injury
outcome factors of pneumonia patients in critical care unit

Conditions: Pneumonia Aggravated

Summary: to determine the risk factor that affect pneumonic patients at the critical care unit regarding the history investigation and clinical data

pneumonia remains a serious illness with important clinical impact . it is defined as acute respiratory tract infection that affect lower respiratory tract ,it is classified as community acquired pneumonia (cap), hospital acquired pneumonia (hap) and ventilator associated pneumonia . in this work we assess the factors that affect the prognosis of critically ill patients with pneumonia regarding the age ,sex ,smoking, other co morbidity as diabetes mellitus, hypertension , liver diseases , kidney diseases, heart diseases and chest diseases, clinical date and investigation .

Eligibility criteria:
inclusion criteria: * 1- age above 18 yrs. 2- critically ill patients admitted to icu with clinical manifestations of pneumonia in assuit university hospital exclusion criteria: * 1- age below 18 yrs. 2- patients don't have critical illness 3- patient who refused to contribute in this study
impact of periodontal intervention on vascular dysfunction

Conditions: Chronic Periodontitis; Prehypertension

Summary: the purpose of this study is to determine the effect of periodontal intervention on vascular dysfunction among chinese prehypertensive adults with moderate to severe periodontal disease.

periodontitis is one of the low-grade chronic diseases, and it is the principal cause of tooth loss among middle-aged and elderly. recently, epidemiological data indicate that patients with periodontitis are associated with increases in blood pressure levels and hypertension prevalence. furthermore, studies from cross-sectional investigations demonstrate that hypertensive patients with periodontitis may enhance the risk and degree of vascular damage. therefore, periodontal therapy is a novel therapeutic strategy to prevent the occurrence of bp elevation and retard the development vascular injury. the term "prehypertension" indicates those with bps ranging from 120 to 139 mm hg systolic and/or 80 to 89 mm hg diastolic blood pressure. accumulating evidence suggests that subjects with prehypertension is associated with higher incidence of atherosclerotic vascular disease. however, until now there are no available data to investigate the influence of periodontitis on prehypertension and whether periodontal intervention may reduce the bp rise in subjects with prehypertension and improve the vascular function. we hypothesized that periodontitis leads to elevation in bp and periodontal therapy improves vascular function in subjects with prehypertension. to address these assumptions, the present study is designed to study the effect of periodontal intervention on blood pressure and vascular function and inflammatory biomarkers among chinese prehypertensive adults with moderate to severe periodontal disease, and determine whether intensive periodontal therapy improves these measures over a 6-month follow-up period.

Eligibility criteria:
inclusion criteria: 1. subjects must be 18 years of age or older 2. moderate to severe generalized periodontitis(probing pocket depths of \>6 mm and marginal alveolar bone loss of \>30%) with 50% or more of their teeth affected 3. have at least 16 natural teeth excluding third molars 4. bps ranging from 120 to 139 mm hg systolic and/or 80 to 89 mm hg diastolic blood pressure 5. provide informed consent and willingness to cooperate with the study protocol exclusion criteria: 1. history of antibiotic use in the previous three months 2. pregnant or lactating females 3. systemic diseases such as diabetes, hiv/aids, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases 4. medical history of cardiovascular disease: acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular blockade, peripheral vascular disease, cerebrovascular accident, hypertension 5. patients who received periodontal treatment within the last 6 months 6. patients who require antibiotic prophylaxis before examination or treatment 7. patients with mental retardation and dementia

Keywords: periodontitis prehypertension periodontal intervention
to evaluate the safety and preliminary efficacy of intravitreal exg202 injection in patients with wet (neovascular) age-related macular degeneration (wamd)

Conditions: Wet Age-related Macular Degeneration (wAMD); Wet Age-related Macular Degeneration

Summary: the goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of exg202 in subjects with neovascular age-related macular degeneration (namd).

exg 202 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (namd). neovascular amd is the main cause of blindness among elderly individuals. the available therapies for treating namd require life-long intravitreal (ivt) injections every 4-12 weeks to maintain efficacy. administration of exg202 has the potential to treat namd by providing durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients. exg 202 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with namd receiving anti-vegf therapy in clinical practice.

Eligibility criteria:
inclusion criteria: 1. male or female, aged ≥50 years old; 2. the study eye must meet the following criteria: a. diagnosed of wamd and current active lesions; active, defined as the presence of any of the following lesions in the macular area upon oct examination: a) intraretinal hemorrhage or fluid; b) subretinal fluid; c) subretinal hemorrhage; b. the bcva score tested during screening using the etdrs eye chart (see appendix 3 for details) must be between 73-19 letters (including boundary values), (equivalent to snellen visual acuity of 20/40 to 20/400); 3. clinically meaningful response to standard anti-vegf therapy within 6 months before screening or during the lead-in period of screening. 4. the subject has clear refractive media and sufficient pupil dilation at the time of screening to obtain high-quality retinal images for confirmation of diagnosis; 5. subjects (including male subjects) have no pregnancy plans during the screening period and the entire trial period and voluntarily take effective contraceptive measures and have no sperm or egg donation plans; 6. voluntarily participate in this clinical trial, understand the research procedures and sign the informed consent form before screening; have good compliance and are willing to abide by the research procedures. exclusion criteria: 1. the study eye has any eye disease other than wamd that may affect central vision and/or macular detection (such as macular hole, macular epiretinal membrane, etc.); 2. the study eye has a history of retinal detachment or retinal detachment during the screening period (such as rhegmatogenous retinal detachment, tractional retinal detachment, etc.); 3. the study eye has mnv caused by reasons other than wamd (such as diabetic retinopathy, pathological myopia, retinal vein occlusion, angioid streak disease, ocular histoplasmosis, trauma, etc.), and a history of macular pathology unrelated to wamd; 4. the study eye plans to undergo any intraocular surgery during the study period;

Keywords: wamd aav
efficacy and safety of dec103 in pain control associated to intrauterine device (iud) insertion

Conditions: Pain

Summary: the purpose of this study is to evaluate the efficacy and safety of dec103 in the pain control associated with iud insertion in women with 18 to 49 years.

the dec103 treatment is composed by two different medications that are already available in brazilian market. one is a sublingual pill and the other is an oral one. the participants must take 02 (two) pills of the sublingual formulation and 01 (one) of the oral formulation.

Eligibility criteria:
inclusion criteria: * patient has given written informed consent to participate in the study prior to admission; * female patients aged between 18 and 49 years old; * first iud users; * nulliparous women. exclusion criteria: * any finding or clinical observation (clinical/physical evaluation) or laboratory condition that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical trial or presence of uncontrolled chronic disease(s); * presence of chronic pelvic pain and any uterine malformation; * presence of psychiatric disorder; * chronic use of medications that interfere with the pain threshold, for example: antidepressants and anticonvulsants; * use of analgesics and/or ant-inflammatory in the last 24 hours prior the procedure; * any sign or symptom of vaginal or cervical infection; * participants with any contraindication to one or both medicines that constitute the dec103 treatment; * actual abuse of alcohol or drugs; * participants who are nursing; * presence of known allergy or hypersensitivity to the components of the drugs used during the clinical trial; * participants with a current medical history of cancer and/or cancer treatment in the last five (05) years; * participation in a clinical research protocol in the last 12 months (cns resolution 251, of august 7, 1997, item iii, subitem j), unless the investigator judges that there may be a direct benefit to it.

Keywords: pain iud insertion
the baby-saver kit: clinical testing of a device for neonatal resuscitation with intact cord in uganda

Conditions: Birth Asphyxia; Neonatal Resuscitation; Maternal Distress

Summary: to examine the usability, safety and acceptability of the babysaver kit: a novel device for neonatal resuscitation in a low-income region in africa

the babysaver kit will be used for any delivery in which the baby requires resuscitation according to the hospital policy, national guidelines(ministry of health, 2016) and who policy(world health organization, 2014) the target sample size for observation will be 30 babies requiring resuscitation at mbale regional referral hospital delivery suite. the researchers will observe midwives and mothers during the process of resuscitation. this will be a non-participant observation. the researchers will collect data on: demographics, the timing of cord clamping, time to establish ventilation, intervention provided on the kit, post-resuscitation temperature, need to move the baby to provide extra care, and notes of the ease of use or challenges experienced with the kit. the researchers will ask health workers for their views of the usability of the kit in comparison to the equipment in current use. the researchers have developed a usability checklist to assess how health workers are using the babysaver kit.

Eligibility criteria:
inclusion criteria: * as this is the first delivery suite to use the kit in a clinical setting, we will include only low-risk babies in this study. every low-risk birth that will need neonatal resuscitation will be selected and observations made for the use of the babysaver resuscitation kit. exclusion criteria: * high risk deliveries will be excluded, namely * babies born before 34 weeks' gestation, * babies with life threatening malformations or significant intrapartum asphyxia
perineural dexamethasone in supraclavicular brachial plexus block for anesthesia after pediatric hand/wrist surgery

Conditions: Wrist Disease; Hand Injuries; Wrist Injuries; Hand Disease; Hand Injuries and Disorders

Summary: effect of perineural dexamethasone on the duration of supraclavicular brachial plexus block for anesthesia after pediatric hand/wrist surgery

this study is proposed to explore the effect of perineurial dexamethasone on the duration of supraclavicular brachial plexus block for analgesia after pediatric ankle surgery. after hand and wrist surgery, children need good analgesia. peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe. the safety of local anesthesia is essential in children due to the much lower toxicity threshold of local anesthetics. an effective adjuvant, such as dexamethasone, could allow for a higher dilution of local anesthetics while maintaining and enhancing their analgesic effect. there is considerable research where intravenous and perineural dexamethasone use has been compared in adults. however, there is a massive lack of research regarding children. in this study, investigators compare different doses of perineural dexamethasone. groups 2 and 3 have dexamethasone doses of 0.1mg/kg and 0.05mg/kg added to local anesthetic. the investigator's goal is to find a dexamethasone dose that is as low as possible but simultaneously covers the need for good pain relief and fast recovery postoperatively.

Eligibility criteria:
inclusion criteria: * children scheduled for hand/wrist surgery * body weight \> 5kg exclusion criteria: * infection at the site of the regional blockade * coagulation disorders * immunodeficiency * asa= or \>4 * steroid medication in regular use
clinical study of fasudil hydrochloride and pd1 inhibitor combined with androgen deprivation in neoadjuvant therapy of prostate cancer

Conditions: Prostate CA

Summary: the high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (psa). at the same time, few trials reported pathological complete response (pcr) and minimal residual lesion (mrd). the purpose of this project is to verify the therapeutic effect of fasudil hydrochloride and pd1 inhibitor combined with androgen deprivation in patients with locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through randomized controlled clinical trials, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.

this study will divide patients into two sections, and eligible patients will be enrolled. patients with locally advanced prostate cancer or oligometastatic prostate cancer were assigned to either fasudil hydrochloride and pd1 inhibitor combined androgen deprivation therapy or placebo combined androgen deprivation therapy based on a computer-generated random sequence. in addition to routine androgen deprivation therapy, patients in the treatment group were given 10mg of fasudil hydrochloride on the 1st to 5th day and pd-1 monoclonal antibody (triprilizumab, 3mg/kg, intravenous drip) on the 5th day. in the placebo group, the same size, color and dosage form of 0.9% sodium chloride injection was used, and the administration was the same as that in the treatment group. after starting the intervention, all patients should be followed up in our hospital every treatment cycle to review blood psa and other indicators. at the end of the treatment cycle, imaging examinations were followed up and radical prostatectomy was performed 3 weeks later (±7 days).

Eligibility criteria:
inclusion criteria: * ① age ≥18 years and ≤85 years; * histologically confirmed prostate cancer without small cell features; * metastatic prostate cancer was identified by imaging examination with ≤5 oligometastases (bone or lymph node metastases) or ct3-4 stages; ④the score of ecog (eastern cooperative oncology group) was 0-1; ⑤ all patients voluntarily sign informed consent, and can adhere to treatment and follow-up; exclusion criteria: * ①any previous or ongoing pca treatment, including radiotherapy, chemotherapy, adt, etc. * previous prostatectomy; * any other serious basic medical, mental, psychological, and other diseases that, in the judgment of the investigator, may affect the treatment of the patient * allergic to the drugs used; ⑤ refuse to undergo radical prostatectomy; ⑥ according to the investigator's judgment, it is not suitable to participate in this clinical trial;
effect of non-surgical periodontal treatment

Conditions: Periodontal Diseases; Adverse Effects

Summary: objective: the objective of this research was to compare the effect of a single session supragingival scaling in a group of pregnant women with periodontal disease with a group that received supra and subgingival scaling. methods: the investigators included 34 pregnant women between 15 and 43 who had at least 4 teeth with probing depth ≥ 4 mm or clinical attachment loss ≥ 3 mm, with bleeding on probing in the same place. women were divided into two groups, the group 1 received supra and subgingival scaling associated with oral hygiene orientation (oho) and the group 2 received only supragingival scaling with oho too.


Eligibility criteria:
inclusion criteria: * pregnant women between 15 and 43 who had at least 4 teeth with probing depth ≥ 4 mm or clinical attachment loss ≥ 3 mm, with bleeding on probing in the same place. exclusion criteria: * patients with systemic disease or who used medications that interfere in the etiological factors of periodontal disease in the last six months, who wore braces and / or prosthetic devices, and women smokers who did not complete treatment.

Keywords: treatment pregnant women periodontitis dental scaling dental plaque
hand rehabilitation based on a robhand exoskeleton in stroke patients: a case series study

Conditions: Stroke

Summary: the following study seeks to provide information regarding to the robhand exoskeleton for hand neuromotor maintenance and/or rehabilitation, developed by the university of valladolid, spain.

the following study seeks to provide information regarding to the robhand exoskeleton for hand neuromotor maintenance and/or rehabilitation, developed by the university of valladolid, spain. the study was carried out by the neurotchnology group of the research and development area of the corporación de rehabilitación club de leones cruz del sur, chile. clinical test were implemented on four subjects with stroke sequelae who participated in two evaluations of manual function and 16 training sessions with the robotic exoskeleton, in order to know the clinical effects on manual function, safety and satisfaction of users who utilize the exoskeleton robhand.

Eligibility criteria:
inclusion criteria: * over 18 years old * active patient at the rehabilitation center club de leones cruz del sur * at least 1 hemorrhagic or ischemic stroke * adequate level of consciousness * paresis of the upper extremities * patient who signed the inform consent exclusion criteria: * comorbidities in the central nervous system * pain in the upper extremity (hand, forearm, arm) * patient who does not sign the informed consent

Keywords: stroke hand rehabilitation exoskeleton